Cover story · Jul 12
Tinnitus Management: Navigating a Fragmented Device Landscape
Recent advances in tinnitus treatment emphasize combination therapies and neuromodulation, yet sustained relief remains an elusive goal for many patients, highlighting the need for more robust clinical evidence.
Read through the lens of
Editorial synthesisCurrent tinnitus management strategies frequently combine sound therapy, counseling, and neuromodulation techniques. Clinicians should evaluate devices based on their evidence for sustained efficacy, particularly in reducing tinnitus loudness and improving quality of life (e.g., THI scores). Safety profiles of non-invasive neuromodulation devices are generally favorable, but trials often show a significant placebo effect. Understanding the specific auditory and neurological profiles of patients may help in tailoring treatment choices, though definitive biomarkers remain elusive.
From the desk
The wire
Fresh reporting from the ProjMed editorial desk — every piece evidence-graded and cited.
regulatory
GE HealthCare Clears FDA 510(k) for Voluson Expert Ultrasound Systems
ProjMed Editorial Desk · 3 min
regulatory
Roche Diagnostics Secures 510(k) for Elecsys EBV VCA IgG Assay
ProjMed Editorial Desk · 3 min
regulatory
CMT Health's Profoject Safety Sliding Blood Collection Set Receives FDA 510(k) Clearance
ProjMed Editorial Desk · 4 min
regulatory
Rivarp Medical Clears FDA 510(k) for Kentrospine Viktr-MIS® Pedicle Screw System
ProjMed Editorial Desk · 4 min
regulatory
E-Fit's Ultima System Cleared by FDA for Aesthetic Applications
ProjMed Editorial Desk · 3 min
regulatory
Inari Medical Secures FDA 510(k) Clearance for Triever Duo Catheter
ProjMed Editorial Desk · 4 min
The ProjMed twist · 01
One story. Three expert lenses.
Every article is rewritten in real time for the reader in the room — clinician, investor, or patient. Same facts, same citations, different depth.
Clinician
Trial design, endpoints, dosing, safety signals — the way a fellow would brief you.
Sample takeaway
Endpoint hit, but Kaplan-Meier separation only after month 6.
Investor
Revenue impact, competitive moat, reimbursement pathway, pipeline overlap.
Sample takeaway
Every 100 bps of penetration = ~$85M in incremental FY revenue.
Patient
Plain-language explanations, real-world availability, questions to ask your care team.
Sample takeaway
Covered by most commercial plans; ask about the specific catheter used.
The ProjMed twist · 02
Regulatory radar
FDA 510(k) clearances and device recalls — streamed directly from openFDA, the FDA's official public data API. Every row links to the primary record.
The ProjMed Briefing
The medtech newsletter that reads like a briefing, not a blog.
Six mornings a week. Every headline evidence-graded, every claim cited. No promoted posts, ever.